Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02116335 · ClinicalTrials.gov registry record · NA

Endothelin Receptor Function and Acute Stress

A NA study of Hypertension, sponsored by Augusta University.

Active
Registry status
NA
Development phase
320
Enrollment target
1
Study location

NCT02116335: Active NA study of Hypertension, sponsored by Augusta University.

NCT02116335 is a NA study of Hypertension that is active but no longer recruiting, run by Augusta University. The registered enrollment target is 320 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02116335, a NA study of Hypertension, is active but no longer recruiting, sponsored by Augusta University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
320 participants
Enrollment target
1
Study location

Study Summary

Our bodies respond differently to stress. Animal studies by the investigators have found that endothelin-1 plays a role in regulating blood pressure in response to stress. This study is an extension of the investigators previous animal work to evaluate the role of endothelin-1 during stress in humans.

Primary Outcome

Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Bosentan

Study Locations (1)

Georgia

  • Georgia Regents University - Augusta

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2015-06
Est. Completion 2026-01
Phase NA
Augusta University

106 total trials

What the registry record for NCT02116335 still lists

NCT02116335 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02116335 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02116335 about?

NCT02116335 is a clinical study titled "Endothelin Receptor Function and Acute Stress". Our bodies respond differently to stress. Animal studies by the investigators have found that endothelin-1 plays a role in regulating blood pressure in response to stress. This study is an extension of the investigators previous animal work to evaluate the role of endothelin-1 during stress in human...

What is the current status of trial NCT02116335?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2015-06. Estimated completion is 2026-01.

What conditions does trial NCT02116335 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT02116335?

The interventions under investigation include: Placebo (DRUG), Bosentan (DRUG).

Who is sponsoring clinical trial NCT02116335?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02116335 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02116335's enrollment target sits among peer trials

320 161st of 470 higher than 310 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

  • NCT03551951 · 320 participants

    Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02116335, the US trial registry maintained by the National Library of Medicine. NCT02116335 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.